LLYEli Lilly and CompanySigning up patients
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Vestibular Schwannoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 27 (planned)
- Started
- Jan 17, 2025
- Main results expected
- Aug 2029
- Fully finished
- Aug 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Frequency of Adverse Events (AEs)
Measured over: through trial completion, approximately one year
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06517888 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC